MoonLake Immunotherapeutics (MLTX) Return on Capital Employed (2021 - 2026)

MoonLake Immunotherapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 73.0% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 3671.0% year-over-year to 73.0%; the TTM figure through Mar 2026 stood at 73.0% (down 3671.0% YoY), while the FY2025 annual figure was 60.35%, down 3052.0% from the prior year.
• Return on Capital Employed was 73.0% for Q1 2026 at MoonLake Immunotherapeutics, down from 65.48% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 131.73% in Q1 2022 to a low of 116.51% in Q3 2022.
• Historically, Return on Capital Employed has averaged 36.65% across 5 years, with a median of 36.28% in 2025.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed surged 13448 bps in 2022, then slumped 22787 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 86.69% in 2022, then jumped by 88 bps to 10.75% in 2023, then tumbled by 180 bps to 30.09% in 2024, then sank by 118 bps to 65.48% in 2025, then slipped by 11 bps to 73.0% in 2026.
• The last three Return on Capital Employed figures came in at 73.0% (Q1 2026), 65.48% (Q4 2025), and 58.94% (Q3 2025), per Business Quant data.